Search Results - "ИНГИБИТОР АНГИОТЕНЗИНПРЕВРАЩАЮЩЕГО ФЕРМЕНТА"

1

Academic Journal

Final results of BIRCOV trial (ARB, ACEI, DRi in COVID-19)

Authors: D.D. Ivanov, M.D. Ivanova, T. Crestanello

Source: Počki, Vol 10, Iss 3, Pp 143-149 (2021)
KIDNEYS; Vol. 10 No. 3 (2021); 143-149
Почки-Počki; Том 10 № 3 (2021); 143-149
Нирки-Počki; Том 10 № 3 (2021); 143-149

Subject Terms: 0301 basic medicine, інгібітори ренін-ангіотензин-альдостеронової системи, інгібітори ангіотензинперетворюючого фермента, блокатори рецепторів ангіотензину, прямі інгібітори реніну, COVID-19, дослідження BIRCOV, 03 medical and health sciences, renin-angiotensin system inhibitors, angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, direct renin inhibitor, COVID-19, BIRCOV trial, 0302 clinical medicine, renin-angiotensin system inhibitors, angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, direct renin inhibitor, covid-19, bircov trial, ингибиторы ренин-ангиотензин-альдостероновой системы, ингибитор ангиотензинпревращающего фермента, блокаторы рецепторов ангиотензина, прямые ингибиторы ренина, COVID-19, исследование BIRCOV, RC870-923, Diseases of the genitourinary system. Urology, 3. Good health

File Description: application/pdf

Access URL: https://kidneys.zaslavsky.com.ua/index.php/journal/article/download/334/429
https://doaj.org/article/d1302dcfcbfe4d21aab34c14a614d0a9
http://kidneys.zaslavsky.com.ua/article/view/239591

View record at OpenAIRE Full Text Finder

2

Academic Journal

Медикаментозна корекція ендотеліальної дисфункції в дітей із хронічним пієлонефритом

Authors: L.I. Vakulenko

Source: Zdorovʹe Rebenka, Vol 13, Iss 7, Pp 659-665 (2018)
CHILD`S HEALTH; Том 13, № 7 (2018); 659-665
Здоровье ребенка-Zdorovʹe rebenka; Том 13, № 7 (2018); 659-665
Здоров'я дитини-Zdorovʹe rebenka; Том 13, № 7 (2018); 659-665

Subject Terms: chronic pyelonephritis, angiotensin-converting enzyme inhibitors, эндотелиальная дисфункция, хронический пиелонефрит, дети, ингибитор ангиотензинпревращающего фермента, L-аргинин, children, L-arginine, ендотеліальна дисфункція, хронічний пієлонефрит, діти, інгібітори ангіотензинперетворюючого ферменту, L-аргінін, endothelial dysfunction, Pediatrics, RJ1-570, 3. Good health

File Description: application/pdf

Access URL: https://doaj.org/article/0443433c8102431786a29a80bc641e1a
http://childshealth.zaslavsky.com.ua/article/view/148919

View record at OpenAIRE Full Text Finder

3

Academic Journal

Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases ; Фармакогенетика в лечении антрациклин-индуцированной кардиотоксичности у женщин без сопутствующих сердечно-сосудистых заболеваний

Authors: E. V. Grakova, K. V. Kopeva, S. N. Shilov, E. N. Berezikova, A. A. Popova, M. N. Neupokoeva, E. T. Ratushnyak, V. V. Kalyuzhin, A. T. Teplyakov, Е. В. Гракова, К. В. Копьева, С. Н. Шилов, Е. Н. Березикова, А. А. Попова, М. Н. Неупокоева, Е. Т. Ратушняк, В. В. Калюжин, А. Т. Тепляков

Contributors: Basic research “Study of the mechanisms of structural and functional myocardial remodeling in different phenotypes in heart failure of ischemic and non-ischemic etiology” No. 122020300045-5, Фундаментальное научное исследование «Изучение механизмов структурного и функционального ремоделирования миокарда при разных фенотипах хронической сердечной недостаточности ишемической и неишемической этиологии» № 122020300045-5

Source: Bulletin of Siberian Medicine; Том 21, № 4 (2022); 44-53 ; Бюллетень сибирской медицины; Том 21, № 4 (2022); 44-53 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2022-21-4

Subject Terms: ингибитор ангиотензинпревращающего фермента, heart failure, gene polymorphisms, β-blocker, angiotensin-converting enzyme inhibitor, сердечная недостаточность, полиморфизмы генов, β-адреноблокатор

File Description: application/pdf

Relation: https://bulletin.ssmu.ru/jour/article/view/5020/3301; https://bulletin.ssmu.ru/jour/article/view/5020/3326; Тепляков А.Т., Шилов С.Н., Попова А.А., Гракова Е.В., Березикова Е.Н., Неупокоева М.Н. и др. Состояние сердечно-сосудистой системы у больных с антрациклиновой кардиомиопатией. Бюллетень сибирской медицины. 2017;16(3):127–136. DOI:10.20538/1682-0363-2017-3-127136.; Kheiri B., Abdalla A., Osman M., Haykal T., Chahine A., Ahmed S. et al. Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity. Am. J. Cardiol. 2018;122(11):1959–1964. DOI:10.1016/j.amjcard.2018.08.039.; McCune C., McGowan M., Johnston R., McCarthy A., Watson C., Dixon L. The prevalence of late anthracycline induced cardiotoxicity in survivors of childhood malignancy in Northern Ireland. Heart. 2019;105:A52. DOI:10.1136/heartjnl-2019ICS.64.; Volkova M., Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr. Cardiol. Rev. 2011;7(4):214–220. DOI:10.2174/157340311799960645.; Janbabai G., Nabati M., Faghihinia M., Azizi S., Borhani S., Yazdani J. Effect of enalapril on preventing anthracycline-induced cardiomyopathy. Cardiovasc. Toxicol. 2017;17(2):130– 139. DOI:10.1007/s12012-016-9365-z.; Cardinale D., Colombo A., Lamantia G., Colombo N., Civelli M., De Giacomi G. et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol. 2010;19;55(3):213–220. DOI:10.1016/j.jacc.2009.03.095.; Aminkeng F., Ross C.J., Rassekh S.R., Hwang S., Rieder M.J., Bhavsar A.P. et al. CPNDS Clinical Practice Recommendations Group. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br. J. Clin. Pharmacol. 2016;82(3):683–695. DOI:10.1111/bcp.13008.; Elitok A., Oz F., Cizgici A.Y., Kilic L., Ciftci R., Sen F. et al. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up. Cardiol. J. 2014;21(5):509–515. DOI:10.5603/CJ.a2013.0150.; Bansal N., Adams M.J., Ganatra S., Colan S.D., Aggarwal S., Steiner R. et al. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardiooncology. 2019;2;5:18. DOI:10.1186/s40959-019-0054-5.; Book W.M. Carvedilol: a nonselective β blocking agent with antioxidant properties. Congestive Heart Failure. 2002;8:173– 190. DOI:10.1111/j.1527-5299.2002.00718.x.; Nabati M., Janbabai G., Baghyari S., Esmaili K., Yazdani J. Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J. Cardiovasc. Pharmacol. 2017;69(5):279–285. DOI:10.1097/FJC.0000000000000470.; Avila M.S., Ayub-Ferreira S.M., de Barros Wanderley M.R. et al. Carvedilol for Prevention of ChemotherapyRelated Cardiotoxicity: The CECCY Trial. J. Am. Coll. Cardiol. 2018;22;71(20):2281–2290. DOI:10.1016/j.jacc.2018.02.049.; Guglin M., Krischer J., Tamura R., Fink A., Bello-Matricaria L., McCaskill-Stevens W. et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J. Am. Coll. Cardiol. 2019;11;73(22):2859–2868. DOI:10.1016/j.jacc.2019.03.495.; Cardinale D., Colombo A., Sandri M., Lamantia G., Colombo N., Civelli M. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;5;114(23):2474–2481. DOI:10.1161/CIRCULATIONAHA.106.635144.; Silber J.H., Cnaan A., Clark B.J., Paridon S.M., Chin A.J., Rychik J. et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. 2004;1;22(5):820–828. DOI:10.1200/JCO.2004.06.022.; Bosch X., Rovira M., Sitges M., Domènech A., Ortiz-Pérez J.T., de Caralt T.M. et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J. Am. Coll. Cardiol. 2013;11;61(23):2355–2362. DOI:10.1016/j.jacc.2013.02.072.; Nazarenko M.S., Markov A.V., Sleptsov A.A. et al. Comparative analysis of gene expression in vascular cells of patients with advanced atherosclerosis. Biomed. Khim. 2018;64(5):416–442. DOI:10.18097/PBMC20186405416.; Brodde O.E. Beta1and beta2-adrenoceptor polymorphisms and cardiovascular diseases. Fundam. Clin. Pharmacol. 2008;22(2):107–125. DOI:10.1111/j.1472-8206.2007.00557.x.; Baudhuin L.M., Miller W.L., Train L., Bryant S., Hartman K.A., Phelps M. et al. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Am. J. Cardiol. 2010;1;106(3):402–408. DOI:10.1016/j.amjcard.2010.03.041.; Metra M., Covolo L., Pezzali N., Zacà V., Bugatti S., Lombardi C. et al. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc. Drugs Ther. 2010;24(1):49–60. DOI:10.1007/s10557-010-6220-5.; Chen L., Meyers D., Javorsky G., Burstow D. et al. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet. Genomics. 2007;17(11):941–949. DOI:10.1097/FPC.0b013e3282ef7354.; Luzum J.A., Sweet K.M., Binkley P.F., Schmidlen T.J., Jarvis J.P., Christman M.F. et al. CYP2D6 genetic variation and beta-blocker maintenance dose in patients with heart failure. Pharm. Res. 2017;34(8):1615–1625. DOI:10.1007/s11095017-2104-8.; Shihmanter R., Nulman I., Goland S., Caspi A., Bar-Haim A., Harary I. et al. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure. J. Clin. Pharm. Ther. 2014;39(4):432–438. DOI:10.1111/jcpt.12154.; Katsarou M.S., Karathanasopoulou A., Andrianopoulou A., Desiniotis V., Tzinis E., Dimitrakis E. et al. Beta 1, Beta 2 and Beta 3 adrenergic receptor gene polymorphisms in a southeastern European population. Front. Genet. 2018;28;9:560. DOI:10.3389/fgene.2018.00560.; Uemura K., Nakura J., Kohara K. Miki T. Association of ACE I/D polymorphism with cardiovascular risk factors. Hum Genet. 2000; 107(3):239-42. doi:10.1007/s004390000358.; Niu T., Chen X., Xu X. Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications. Drugs. 2002;62(7):977–993. DOI:10.2165/00003495-200262070-00001.; https://bulletin.ssmu.ru/jour/article/view/5020

Availability: https://bulletin.ssmu.ru/jour/article/view/5020
https://doi.org/10.20538/1682-0363-2022-4-44-53

View record from BASE

4

Academic Journal